Sarah Busch, PhD brings deep expertise in cell therapies for CNS disease and injury to her position as Associate Director of Neuroscience at Athersys, Inc. Since 2010, she has focused on advancing the MultiStem® cell therapy platform through preclinical development in ischemic stroke, spinal cord injury, multiple sclerosis, and traumatic brain injury among others. Dr. Busch is proficient in the development pathways for cellular therapeutics, including models for validation and improvement of the cell product, cell-based potency assays, animal models and clinical trial design. Dr. Busch has authored several peer reviewed manuscripts on spinal cord injury with a focus on the interaction between neural and immune cells. Further, she is the inventor on several patents involving the use of stem cells for treating disease. Dr. Busch contributed to realization of grant funding from the Ohio Third Frontier, and received a Small Business Initiated Research Grant through the National Institute of Neurological Disease and Stroke. Most recently, she was awarded a Department of Defense grant encompassing the regulatory and planning steps necessary to submit an Investigational New Drug application to the United States FDA for the use of MultiStem® in a Phase II clinical trial for treating patients suffering from acute spinal cord injuries. Dr. Busch received her PhD in 2009 from Case Western Reserve University in the laboratory of Dr. Jerry Silver. She is an active member of the National Center for Regenerative Medicine, the Society for Neuroscience, the Spinal Cord Outcomes Partnership Endeavor.